Wang Wen-Jin, Xin Zhuo-Yang, Su Xuxian, Hao Liang, Qiu Zijie, Li Kang, Luo Yumei, Cai Xu-Min, Zhang Jianquan, Alam Parvej, Feng Jing, Wang Shaojuan, Zhao Zheng, Tang Ben Zhong
Clinical Translational Research Center of Aggregation-Induced Emission, The Second Affiliated Hospital, School of Medicine, School of Science and Engineering, Shenzhen Institute of Aggregate Science and Technology, The Chinese University of Hong Kong, Shenzhen (CUHK-Shenzhen), Shenzhen, Guangdong 518172, China.
Department of Chemistry, The Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction, Division of Life Science, State Key Laboratory of Molecular Neuroscience, and Department of Biological and Chemical Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR 999077, China.
ACS Nano. 2025 Jan 14;19(1):281-306. doi: 10.1021/acsnano.4c14887. Epub 2025 Jan 2.
A revolutionary transformation in biomedical imaging is unfolding with the advent of aggregation-induced emission luminogens (AIEgens). These cutting-edge molecules not only overcome the limitations of traditional fluorescent probes but also improve the boundaries of high-contrast imaging. Unlike conventional fluorophores suffering from aggregation-caused quenching, AIEgens exhibit enhanced luminescence when aggregated, enabling superior imaging performance. This review delves into the molecular mechanisms of aggregation-induced emission (AIE), demonstrating how strategic molecular design unlocks exceptional luminescence and superior imaging contrast, which is crucial for distinguishing healthy and diseased tissues. This review also highlights key applications of AIEgens, such as time-resolved imaging, second near-infrared window (NIR-II), and the advancement of AIEgens in sensitivity to physical and biochemical cue-responsive imaging. The development of AIE technology promises to transform healthcare from early disease detection to targeted therapies, potentially reshaping personalized medicine. This paradigm shift in biophotonics offers efficient tools to decode the complexities of biological systems at the molecular level, bringing us closer to a future where the invisible becomes visible and the incurable becomes treatable.
随着聚集诱导发光分子(AIEgens)的出现,生物医学成像正在经历一场革命性的变革。这些前沿分子不仅克服了传统荧光探针的局限性,还拓展了高对比度成像的边界。与遭受聚集猝灭的传统荧光团不同,AIEgens在聚集时表现出增强的发光,从而实现卓越的成像性能。本综述深入探讨了聚集诱导发光(AIE)的分子机制,展示了策略性分子设计如何解锁非凡的发光和卓越的成像对比度,这对于区分健康组织和患病组织至关重要。本综述还强调了AIEgens的关键应用,如时间分辨成像、第二近红外窗口(NIR-II)以及AIEgens在对物理和生化线索响应成像的敏感性方面的进展。AIE技术的发展有望将医疗保健从早期疾病检测转变为靶向治疗,有可能重塑个性化医疗。生物光子学中的这一范式转变提供了有效的工具,以在分子水平上解码生物系统的复杂性,使我们更接近一个不可见变为可见、不治之症变为可治之症的未来。